Merck EPS - Earnings per Share 2010-2024 | MRK
Merck annual and quarterly earnings per share history from 2010 to 2024. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
- Merck EPS for the quarter ending March 31, 2024 was $1.87, a 68.47% increase year-over-year.
- Merck EPS for the twelve months ending March 31, 2024 was $0.90, a 82.42% decline year-over-year.
- Merck 2023 annual EPS was $0.14, a 97.55% decline from 2022.
- Merck 2022 annual EPS was $5.71, a 11.09% increase from 2021.
- Merck 2021 annual EPS was $5.14, a 84.89% increase from 2020.
| Merck Annual EPS |
| 2023 |
$0.14 |
| 2022 |
$5.71 |
| 2021 |
$5.14 |
| 2020 |
$2.78 |
| 2019 |
$3.81 |
| 2018 |
$2.32 |
| 2017 |
$0.87 |
| 2016 |
$1.41 |
| 2015 |
$1.56 |
| 2014 |
$4.07 |
| 2013 |
$1.47 |
| 2012 |
$2.00 |
| 2011 |
$2.02 |
| 2010 |
$0.28 |
| 2009 |
$5.65 |
| Merck Quarterly EPS |
| 2024-03-31 |
$1.87 |
| 2023-12-31 |
$-0.48 |
| 2023-09-30 |
$1.86 |
| 2023-06-30 |
$-2.35 |
| 2023-03-31 |
$1.11 |
| 2022-12-31 |
$1.18 |
| 2022-09-30 |
$1.28 |
| 2022-06-30 |
$1.55 |
| 2022-03-31 |
$1.70 |
| 2021-12-31 |
$1.48 |
| 2021-09-30 |
$1.80 |
| 2021-06-30 |
$0.61 |
| 2021-03-31 |
$1.25 |
| 2020-12-31 |
$-0.82 |
| 2020-09-30 |
$1.16 |
| 2020-06-30 |
$1.18 |
| 2020-03-31 |
$1.26 |
| 2019-12-31 |
$0.92 |
| 2019-09-30 |
$0.74 |
| 2019-06-30 |
$1.03 |
| 2019-03-31 |
$1.12 |
| 2018-12-31 |
$0.69 |
| 2018-09-30 |
$0.73 |
| 2018-06-30 |
$0.63 |
| 2018-03-31 |
$0.27 |
| 2017-12-31 |
$-0.38 |
| 2017-09-30 |
$-0.02 |
| 2017-06-30 |
$0.71 |
| 2017-03-31 |
$0.56 |
| 2016-12-31 |
$-0.20 |
| 2016-09-30 |
$0.78 |
| 2016-06-30 |
$0.43 |
| 2016-03-31 |
$0.40 |
| 2015-12-31 |
$0.35 |
| 2015-09-30 |
$0.64 |
| 2015-06-30 |
$0.24 |
| 2015-03-31 |
$0.33 |
| 2014-12-31 |
$2.51 |
| 2014-09-30 |
$0.31 |
| 2014-06-30 |
$0.68 |
| 2014-03-31 |
$0.57 |
| 2013-12-31 |
$0.27 |
| 2013-09-30 |
$0.38 |
| 2013-06-30 |
$0.30 |
| 2013-03-31 |
$0.52 |
| 2012-12-31 |
$0.30 |
| 2012-09-30 |
$0.56 |
| 2012-06-30 |
$0.58 |
| 2012-03-31 |
$0.56 |
| 2011-12-31 |
$0.48 |
| 2011-09-30 |
$0.55 |
| 2011-06-30 |
$0.65 |
| 2011-03-31 |
$0.34 |
| 2010-12-31 |
$-0.16 |
| 2010-09-30 |
$0.11 |
| 2010-06-30 |
$0.24 |
| 2010-03-31 |
$0.09 |
| 2009-12-31 |
$2.63 |
| 2009-09-30 |
$1.61 |
| 2009-06-30 |
$0.74 |
| 2009-03-31 |
$0.67 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$325.871B |
$60.115B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
